Apyx® Medical (APYX)
Supplies Renuvion and AYON systems alongside an OEM segment.
Something off on this page? Send us feedback.
The Surgical Aesthetics segment sells Renuvion helium-plasma products and the AYON Body Contouring System to cosmetic surgery. An OEM segment complements the business, while J-Plasma serves the hospital surgical market.
Renuvion helium-plasma products and the AYON Body Contouring System form the Surgical Aesthetics segment, which serves the cosmetic-surgery market. AYON integrates fat removal, closed-loop contouring, Renuvion tissue contraction, and electrosurgical capabilities.
Following the sale of its Core business, the company concentrated its advanced-energy business on cosmetic surgery and directs marketing and sales initiatives toward that market. An OEM segment remains alongside Surgical Aesthetics, while J-Plasma is marketed to the hospital surgical market.
Product use and commercial adoption are shaped by FDA-cleared indications. The FDA issued a Safety Communication concerning use of Advanced Energy products outside their cleared indications.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 13, 2026 | H.C. Wainwright | Initiate | Rating: —Target: — | Target: $7 |
| Mar 11, 2026 | Craig-Hallum | Reiterate | Rating: —Target: — | Target: $6 |
| Mar 11, 2026 | BTIG | Upgrade | ||
| Dec 15, 2025 | Roth Capital | Target | Target: — | Target: $6 |
| Nov 12, 2025 | Citizens | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $27.6M · Total debt $39.6M · Total assets $61.1M · Shareholders' equity $10.7M
- Revenue
- $13.9M
- Operating income
- −$1.8M
- Net income
- −$3.2M
No dividends on record.
| Institutions | 50.59% | 21.31M shares | |
|---|---|---|---|
| 70 holders · as of Jun 30, 2026 | |||
| Insiders | 12.94% | 5.45M shares | |
| 6 holders · as of Jul 2, 2026 | |||
| Other | 36.47% | 15.36M shares | |
| remainder | |||
42.12M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Royce & Associates LPInstitution | 7.77% | 3.27M | as of Jun 30, 2026 |
Nantahala Capital Management, LLCInstitution | 7.76% | 3.27M | as of Jun 30, 2026 |
William Weeks VanderfeltInsider | 7.50% | 3.16M | filed Jan 9, 2020 |
Archon Capital Management LLCInstitution | 6.28% | 2.64M | as of Jun 30, 2026 |
Stavros G. VizirgianakisInsiderdirector | 4.15% | 1.75M | filed May 9, 2024 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- InMode
Minimally invasive RF body contouring and tissue contraction overlap
- Bausch Health
Direct overlap in surgical liposuction and aesthetic body contouring
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Apyx® Medical | $2.95 | 0.00% | $122.5M | — | — | 2.1 | +22.1% |
| InMode | $14.45 | 0.00% | $833.5M | 11.8 | 10.9 | 2.2 | −0.0% |
| Bausch Health | $5.81 | +0.09% | $2.11B | — | 1.3 | 0.2 | +11.2% |
| Median | 11.8 | 6.1 | 1.2 | +5.6% |